Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide).

In patients with ischemic cardiomyopathy, mortality rate and quality of life are unsatisfactory.

The researchers investigated the effects of the metabolic agent trimetazidine (TMZ) on exercise tolerance and prognostic markers B-type natriuretic peptide (BNP) and cardiac troponin T (cTnT) plasma levels.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

Patients were evaluated at baseline, at 1 month, and at 6 months (echocardiography and 6-minute walking test).

At enrollment and at the end of follow-up, blood testing was performed for determination of BNP and cTnT plasma levels.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The researchers investigated the effects of the metabolic agent trimetazidine (TMZ) on exercise tolerance and prognostic markers B-type natriuretic peptide (BNP) and cardiac troponin T (cTnT) plasma levels.

The subject headings attached to it are Exercise Tolerance, Myocardial Ischemia, Natriuretic Peptide, Brain, Trimetazidine, Troponin T and Vasodilator Agents.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (American heart journal), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.